In the subgroup of newer incretin-based therapies (including semaglutide and tirzepatide), the average regain rate was higher (about 1.8 pounds per month), which tracks with the fact that these drugs also produce greater initial weight loss
Gallbladder symptoms such as nausea and abdominal discomfort can overlap with common GLP-1 side effects, making the two easy to mistake for one another
Semaglutide targets the GLP-1 pathway, while Tirzepatide works on both GLP-1 and GIP pathways to provide broader support for appetite control and metabolism
Designed to support quicker recovery after physical exertion or injury by replenishing nutrients, reducing inflammation, and enhancing performance
At the same time, many clinical trials have shown the effectiveness of l-carnitine in relieving fatigue caused by the treatment of diseases such as cancer, MS, and many other diseases